Arrowhead Pharmaceuticals Inc (ARWR) Expected to Announce Earnings of -$0.13 Per Share

Share on StockTwits

Brokerages predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report ($0.13) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Arrowhead Pharmaceuticals’ earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.22). Arrowhead Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, December 11th.

On average, analysts expect that Arrowhead Pharmaceuticals will report full year earnings of ($0.64) per share for the current year, with EPS estimates ranging from ($0.76) to ($0.56). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.90) to $0.30. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative return on equity of 59.39% and a negative net margin of 400.13%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.62 million.

Several research analysts have recently commented on the company. BidaskClub lowered Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Chardan Capital reiterated a “buy” rating and issued a $17.50 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $20.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Finally, B. Riley lifted their target price on Arrowhead Pharmaceuticals from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 8th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $16.20.

NASDAQ ARWR traded down $1.21 during mid-day trading on Wednesday, reaching $14.10. 3,142,600 shares of the company’s stock traded hands, compared to its average volume of 1,801,784. Arrowhead Pharmaceuticals has a 1-year low of $2.65 and a 1-year high of $17.50. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.30 billion, a PE ratio of -30.00 and a beta of 1.91.

In related news, CEO Christopher Richard Anzalone sold 164,834 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $14.45, for a total transaction of $2,381,851.30. Following the completion of the transaction, the chief executive officer now owns 1,868,789 shares in the company, valued at approximately $27,004,001.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total value of $280,200.00. Following the transaction, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 284,834 shares of company stock valued at $4,107,051. Insiders own 4.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in Arrowhead Pharmaceuticals by 341.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 340,244 shares of the biotechnology company’s stock valued at $4,628,000 after purchasing an additional 263,205 shares during the period. MetLife Investment Advisors LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $557,000. Metropolitan Life Insurance Co. NY bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $393,000. Macquarie Group Ltd. bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $151,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $244,000. Institutional investors and hedge funds own 58.96% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Recommended Story: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply